Beckwith-Wiedemann syndrome (BWS) is a model human imprinting disorder resulting from altered activity of one or more genes in the 11p15.5 imprinted gene cluster. Approximately 20% of BWS cases have uniparental disomy (UPD) of chromosome 11. Such cases appear to result from mitotic recombination occurring in early embryogenesis and offer a rare opportunity to study mitotic recombination in nonneoplastic cells. We analyzed a cohort of 52 children with BWS and UPD using a panel of microsatellite markers for chromosome 11. All cases demonstrated mosaic paternal isodisomy, and IGF2 and H19 were included in the segment of UPD in all cases. However, the extent of segmental disomy was variable, with no evidence of clustering of the proximal UPD breakpoint. In most cases (92% of those informative) UPD did not involve 11q, but 4 patients demonstrated UPD for the whole of chromosome 11. In contrast to meiotic recombination, the mitotic recombination frequency did not decline near the centromere.
Recombination between chromatids is an essential prerequisite for meiosis I to occur, and the mechanisms and the consequences of meiotic recombination have been studied extensively (reviewed in [1] ). Although mitotic recombination has received less attention, this process occurs frequently in humans and the resulting loss of heterozygosity is an important mechanism of tumor-suppressor inactivation in many human cancers [2] [3] [4] . The increasing application of genome-wide genotyping (e.g., SNP microarrays) and copy number analysis techniques (e.g., array CGH) has highlighted the importance of mitotic recombination in tumorigenesis [5] [6] [7] . Hence there is relatively little information available on mitotic recombination events in nonneoplastic cells, although human disease may result from mitotic recombination affecting imprinted gene regions. Thus mitotic recombination may generate loss of heterozygosity and cells with maternal or paternal uniparental disomy (UPD). Mosaic paternal UPD is classically seen in Beckwith-Wiedemann syndrome (BWS), a model imprinting disorder characterized by pre-and postnatal overgrowth, developmental defects, and susceptibility to embryonal tumors [8, 9] . About 20% of sporadic BWS cases have segmental uniparental disomy involving the imprinted gene cluster at 11p15.5 [10, 11] . While the frequency and phenotype of UPD are well established, the extent to which different regions on chromosome 11 exhibit UPD has not been analyzed in detail. To determine this information and to compare meiotic and mitotic recombination patterns on chromosome 11, we mapped the extent of segmental UPD in 52 children with BWS and UPD.
Results
Clinical features of the patient cohort of children with BWS have been reported previously [12] . While the extent of segmental disomy and proportion of cells with UPD was variable ( Fig. 1 ), in all cases UPD was paternal isodisomy. Four of 52 (8%) patients studied exhibited UPD extending onto the q arm of chromosome 11, and in all of these patients UPD was observed for all informative markers tested (covering >98% of chromosome 11). In 2 cases it was not possible to demonstrate or exclude UPD extending onto the q arm. Of the remaining 46 patients in which the region of UPD did not extend to 11q and in which the breakpoint was mapped on the p arm, 14 Fig. 1 ). Comparison of the centromeric mitotic recombination breakpoint (proximal extent of disomy) to the physical distance and meiotic recombination map ( Fig. 2 ) did not provide strong evidence for mitotic recombination hot spots; however, there was possibly a slight increase in the recombination rate at the centromere.
Two patients did not exhibit UPD at D11S1923 (3.19 Mb, 8.64 cM); patient 1 demonstrated biallelic inheritance and patient 2 was uninformative at D11S1923 (Table 1) ; this marker maps adjacent to CARS, which is thought to delineate the centromeric end of the imprinting cluster. Therefore, the extent of UPD in these patients was mapped more finely. Patient 2 Fig. 1 . The extent of uniparental disomy along chromosome 11 in a group of patients with BWS known to be due to paternal UPD 11p15.5. The markers spanning the BWS critical region are shaded in gray. Black boxes represent regions of allelic imbalance in favor of the paternal allele. Markers that were uninformative or for which no information was available are shaded gray, and regions for which no allelic imbalance was observed are white. All patients continued with the status depicted at D11S2365 for the rest of the q arm except patients 33, 42, 43, 44, 45 (UPD could be excluded at and beyond D11S4459), 34, 46, 47 (UPD could be excluded at and beyond D11S2363), and 48 (UPD could be excluded at and beyond D11S2006). "Tumour" column: WT, Wilms tumor; HB, hepatoblastoma. Fig. 2 . Graph to compare the rate of mitotic and meiotic recombination across the p arm of chromosome 11. The number of UPD cases known to have not recombined is expressed as the proportion of the total number of BWS cases with a breakpoint on 11p (cases uninformative for that marker are excluded). The meiotic recombination data refer to the 45 female and 40 male CEPH probands known to have a recombination event on 11p. Table 1 The extent of disomy in the two patients with the smallest regions of UPD Black boxes represent regions of allelic imbalance in favor of the paternal allele. Areas where UPD could not be proven or excluded are shaded gray, and regions for which no allelic imbalance was observed are white. LOM, loss of maternal methylation; NI, not informative for that marker. exhibited UPD at D11S4088 (2.71 Mb, 7.03 cM); patient 1 was uninformative at this marker, but exhibited UPD for novel microsatellites located at 2.35 and 2.42 Mb. The imprinted region at 11p15.5 includes regions that are differentially methylated between the parental genomes. The H19 differentially methylated region (DMR; located at 1.98 Mb) is paternally methylated and in the methylated state is proposed to promote the expression of IGF2 [13] . The maternally methylated region KvDMR1 is proposed to induce CDKN1C expression in the methylated state [14] . KvDMR1 is located at 2.68 Mb and the methylation status of this region in patient 1 was consistent with UPD, thus mapping the centromeric recombination breakpoint in patient 1 between 2.68 and 3.19 Mb and between 2.7 and 3.70 Mb (D11S4146) in patient 2. All cases demonstrated UPD for the most telomeric markers for which they were informative, suggesting that the telomeric UPD boundary was less than 0.24 Mb from the telomere.
Discussion
Mitotic recombination (and consequent loss of allelic heterozygosity (LOH)) can be a frequent cause of tumor suppressor gene inactivation in cancer, but BWS patients with UPD provide a rare opportunity to investigate human mitotic recombination in nonneoplastic cells. There is relatively little information on nonneoplastic somatic loss of heterozygosity but a high frequency of LOH in normal T lymphocytes was attributed primarily to mitotic recombination [4] . Interestingly it has been suggested that the frequency of mitotic recombination may be increased at telomeric regions but the hot spots for meiotic and mitotic recombination may not coincide [15, 16] . Paternal UPD for 11p15 accounts for approximately 20% of sporadic BWS cases [10, 11] . The 11p15.5 imprinted gene cluster contains many genes [17] , and those thought to be most important in the pathogenesis of BWS include CDKN1C, IGF2, and H19. The region of paternal UPD invariably includes the imprinted gene cluster at 11p15.5; however, the extent of isodisomy along chromosome 11 is variable [18, 19] . We found mosaic paternal isodisomy, consistent with previous reports. Thus UPD appears to have arisen as a postzygotic event due to mitotic recombination in early embryogenesis. Consistent with the mosaicism, hemihypertrophy demonstrates a strong association with UPD in BWS [12, 20, 21] and in some cases isodisomy is detectable in only a subset of tissues tested [22] . This mechanism of UPD in BWS differs from that seen in Prader-Willi and Angelman syndromes, in which maternal heterodisomy and complete paternal isodisomy, respectively, occur either as a result of nondisjunction errors during meiosis [23] [24] [25] or, more frequently, as a result of postzygotic nondisjunction events in the early embryo [26] . It is interesting that we did not find any evidence of nonmosaic paternal isodisomy (as seen for chromosome 15 in Angelman syndrome) in BWS, but we did identify four individuals with mosaic UPD for the whole of chromosome 11. A single similar case has been reported previously [18] , suggesting that in BWS UPD is most frequently due to mitotic recombination in the early embryo and less commonly due to nondisjunction in the early embryo.
A possible explanation for the absence of nonmosaic chromosome 11 paternal isodisomy is that a lack of one or more chromosome 11 maternally expressed genes may lead to embryonic lethality.
The level of UPD mosaicism was variable, with the ratio of paternal to maternal alleles in blood varying between 1.4:1 and 11.3:1; however, we did not have access to the various tissue samples that would be required for a comprehensive study of mosaicism. Identification of tissues with the highest levels of mosaicism might allow more detailed mapping of UPD using SNP microarrays. Postzygotic mitotic recombination followed by uneven distribution of chromatids to daughter cells would produce a mixed population of normal cells, cells with maternal UPD, and cells with paternal UPD. However, analysis of single cells from BWS UPD patients detected only two cell populations, normal and paternal UPD11 [27] . This suggests that cells with paternal UPD11 may have a selective growth advantage and that maternal UPD cells die or partition to different parts of the conceptus.
Genomic instability is frequent in many human cancers and may predispose to mitotic recombination. Individuals with Bloom syndrome have an elevated frequency of sister chromatid exchanges due to a mutation in BLM, which encodes a RecQ helicase that is required for suppressing crossing over during homologous recombination [28, 29] . However, there is no evidence to suggest underlying genomic instability in BWS and so individuals with BWS and UPD provide an opportunity to investigate mitotic recombination events in "normal cells." Genome-wide meiotic recombination rates vary markedly, although recombination is usually more frequent in telomeric regions than in centromeric regions. In addition, meiotic recombination rates at a specific locus may vary between sexes. High-resolution sperm-mapping studies can delineate the presence and nature of male meiotic recombination hot spots [30] , but at much lower resolution mapping (while we considered higher density mapping by microarray, we were concerned that the mosaic nature of the samples would make interpretation difficult) we did not identify regions of mitotic recombination clustering, suggesting that the mechanisms of meiotic and mitotic recombination may differ. In addition we did not identify a common breakpoint region at the chromosome 11q23.3 fragile sites. However, we did observe that 13 of the 48 (27%) individuals with a mapped breakpoint transferred from uniparental to biparental inheritance between D11S1993 (43.57 Mb) and D11S2006 (59.48 Mb). This is interesting as the centromere is located at 51.5-54.5 Mb and meiotic recombination is reduced in the pericentromeric region.
Mouse models of BWS may result from overexpression of Igf2 transgenes or cdkn1c deletion, and BWS children with paternal duplication of 11p15.5 (causing increased IGF2 expression but no effect on CDKN1C) and others with a germ-line maternal allele CDKN1C mutation implicate IGF2 overexpression and/or CDKN1C inactivation in the pathogenesis of BWS. The majority of BWS children with UPD have paternal disomy for both IGF2 and CDKN1C and while all of our cases included the H19 differentially methylated region (DMR1, imprinting center 1) and the IGF2 gene (thus predic-ting increased IGF2 and reduced H19 expression), we found two cases in which it was not possible to tell from microsatellite markers whether CDKN1C was included in the region of UPD. However, in both cases there was loss of maternal allele methylation at KvDMR1 (presumably due to paternal isodisomy). As loss of KvDMR1 methylation is associated with reduced expression of CDKN1C, we would predict that in these cases there would be reduced CDKN1C expression-even if CDKN1C itself mapped outside the region of UPD. Thus it would seem that for BWS cases with UPD, altered expression of IGF2, H19, and CDKN1C is the rule.
Previously we reported that UPD cases with Wilms tumor were more likely to have UPD for the 11p13 WT1 Wilms tumor suppressor gene locus than those without Wilms tumor [12] . Although the difference did not reach statistical significance, this observation was interesting, as some evidence for imprinting at the WT1 locus had been described. Thus Wilms tumors with 11p13 allele loss appear to display preferential maternal allele loss [31] and analysis of WT1 RNA shows that there is variable biallelic expression or partial or complete maternal repression [32] [33] [34] . In addition it has been suggested that an alternative WT1 transcript (AWT1) and the antisense WT1 transcript (WT1-AS, which overlaps the 5′ end of WT1) may be imprinted [35] [36] [37] . These transcripts have a differentially methylated "promoter" and are differentially expressed. It has been shown that WT1-AS transcription can elevate WT1 protein levels in vitro [36] , such that in fetal tissues both alleles are unmethylated and transcription occurs from both alleles; however, in adult tissues the maternal allele has been silenced by methylation, whereas in Wilms tumors without 11p13 LOH the fetal state is retained. Paternal UPD for 11p13 would also have the effect of maintaining the chromosome in the fetal state of biallelic expression of WT1-AS.
Individuals with BWS and UPD represent a valuable resource for the study of mitotic recombination because of the well-defined phenotype, and the subtelomeric location of the 11p15 gene cluster. Thus there is little or no variability in the location of the distal breakpoint, but the proximal breakpoint is very variable. Advances in SNP microarray technology that allow the reliable mapping of mosaic UPD will facilitate the mapping of chromosome 11 disomy in BWS and, for comparison, in human neoplasia [5, 6] .
Methods
Patients were ascertained via a national research study or following referral to the West Midlands Regional Genetics Service for diagnostic testing. Clinical information was collected by a standard questionnaire, inspection of hospital notes, or direct examination. Patients were included in the study following a molecular diagnosis of BWS with UPD irrespective of the original indication for referral.
Samples were obtained from the proband and both parents; DNA was extracted from peripheral blood lymphocytes or tissue samples by standard procedures.
PCR was performed on 20 ng of genomic DNA in a 10-μl total reaction volume containing fluorescently labeled forward primer (0.2 μM), unlabeled reverse primer (0.2 μM), dNTP (0.2 mM) ABGene Taq (0.5 U) in 1× ABGene buffer containing 1.5 mM MgCl 2 . After an initial denaturation step (3 min at 96°C), 26 cycles of amplification were performed (96°C for 30 s, 55°C for 30 s, 72°C for 30 s) followed by a final extension for 10 min at 72°C. The primer sequences used were those of the Research Genetics microsatellite panel except for novel markers generated telomeric to KvDMR1. The primers designed to amplify the dinucleotide repeat located at 2.35 Mb had the sequences forward, 5′-AACCAGTACTGCTATGAACA, and reverse, 5′-AATAGTGCAGCCA-CTTCGGA, and those designed to amplify the repeat at 2.42 Mb had the sequences forward, 5′-TAGCTGAGGAGTCTATGCTA, and reverse. 5′-GAGACAATCACAATGTCCTT.
Alleles were resolved through a 6% polyacrylamide gel on an ABI 377, and the ratio of paternal to maternal allele intensity was determined using the Genotyper software (ABI); a ratio of greater than 1.3:1 in favor of the paternal allele indicated UPD.
Methylation analysis was performed following bisulfite conversion of unmethylated cytosines to uracil. DNA was modified [38] and then amplified by PCR using a fluorescently labeled forward primer; for KvDMR1 methylation analysis the primers used wereW2, 5′-GTTATTTTATATTTAGTTAGTGT-TTTATG, and W4, 5′-TCTTACTAAAAAACTCCCTAAAAATC, as described in [12] . The PCR products were then digested with the restriction enzyme BstUI, which has the recognition site CGCG and hence will cut only modified DNA derived from previously methylated DNA. The fragments were separated on an ABI 377 and the ratio of methylated to unmethylated DNA was determined.
The genetic distances are according to the Marshfield map [39] except for D11S2071, D11S2365, and D11S4463, which were not mapped by Marshfield.
The physical distances are those of NCBI build 35 released May 2004. The CEPH genotype data were obtained from http://www.cephb.fr/cephdb/.
